No-observed-adverse-effect level (NOAEL) in IND Programs

Toxicology studies in drug development help identify potential safety issues and target organs in humans to identify translational markers of potential toxicity in later human trials and they can provide high-quality and reliable data on which to base the safe starting dose in humans. The data from these studies, and particularly the no-observed-adverse-effect level (NOAEL) information is essential for the safe and effective development of new drugs. In this podcast, we discuss the importance of NOAEL information in safety and toxicology studies.

"*" indicates required fields

First Name*

Last Name*

Company*

State*

Country

Email*

Phone*

Please only hit the submit button once.

I AGREE*

By submitting this form I agree that Frontage may process my data in the manner described in Frontage’s Privacy Policy.

Phone

This field is for validation purposes and should be left unchanged.

No-observed-adverse-effect level (NOAEL) in IND Programs

Resources to Consider

Nondetectable Or Minimal Detectable Residue Levels Of...

Best Practices in Managing IND Programs with CROs

Common Errors in IND-enabling Toxicology Programs